In vivo production of proteins
US-2015376648-A1 · Dec 31, 2015 · US
Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
US9505822B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9505822-B2 |
| Application number | US-201414510894-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 9, 2014 |
| Priority date | Jan 18, 2009 |
| Publication date | Nov 29, 2016 |
| Grant date | Nov 29, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting angiogenesis, the method comprising contacting endothelial cells associated with the angiogenesis with a single chain vascular endothelial growth factor (VEGF) variant polypeptide, comprising: a first VEGF polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and having at least one substitution selected from the group consisting of V15A, M18R, R23K, L32S, F36L, E44G, I76T, H86Y, Q87R, and Q89H, and a second VEGF polypeptide…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
- C07K14/515Primary
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9505822B2 cover?
- Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
- Who is the assignee on this patent?
- Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification C07K14/515. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).